Physician Photo

Jason E. Faris, MD

  • Phone: 617-724-4000
Departments
Hematology/Oncology
Department of Medicine

Specialties

  • Cancer Center
  • Liver Cancer
  • Pancreatic Cancer
  • Stomach Cancer
  • Gastrointestinal Cancers
  • Colorectal Cancer
  • Esophageal Cancer
  • Gallbladder Cancer
Clinical Interests
Gastrointestinal Cancers
New therapeutics for patients with GI Cancers
Locations
Boston: Massachusetts General Hospital
Medical Education
MD, Johns Hopkins University School of Medicine
Residency, Massachusetts General Hospital
Fellowship, Dana Farber Cancer Institute
Board Certifications
Internal Medicine, American Board of Internal Medicine
Medical Oncology, American Board of Internal Medicine
Gender
Male
Patient Age Group
Adult
Accepting New Patients
Yes

BiographyDr. Jason Faris attended medical school at the Johns Hopkins School of Medicine.  Following graduation, he completed internship and residency at the Massachusetts General Hospital (MGH), and fellowship training at the Dana Farber Cancer Institute. Midway through fellowship, Dr. Faris served as a Chief Resident in the Department of Medicine at MGH.  Dr. Faris currently is an attending physician with the GI Cancer program at the MGH Cancer Center, and is interested in the evaluation of new therapeutics for GI cancers.  Dr Faris is the principal investigator for several clinical trials open to patients with GI Cancers.  

Publications

View my most recent publications at PubMed

Faris JE, Wo JY.  The controversial role of chemoradiation for patients with locally advanced pancreatic cancer.  Oncologist 2013; 18(9): 981-85.

Faris JE, Ryan DP. Controversy and consensus on management of patients with pseudomyxoma peritonei. 
Curr Treat Options Oncol 2013;14(3): 365-373.

Faris JE, Blaszkowsky LS, McDermott S, et al. FOLFIRINOX in Locally Advanced Pancreatic Cancer. Oncologist. 2013; 18(5):543
Faris JE, Zhu AX. Targeted therapy for biliary tract cancers. J Hepatobiliary Pancreat Sci. 2012 Jul; 19(4):326-36

Faris, JE, Ryan DP. Biomarker-Driven Therapy in the Neoadjuvant Treatment of Colorectal Liver Metastases. Curr Colorectal Cancer Rep 2012; 8(2):143-151

Faris JE, Ryan DP. Trees, forests, and other implications of a BRAF mutant gene signature in patients with BRAF wt disease. J Clin Oncol. 2012 Apr 20; 30(12):1255-7

Faris JE, Arnott J, et al. A phase 2 study of oral MKC-1. Invest New Drugs. 2012 Aug; 30(4):1614-20.

Faris JE, Smith MR. Metabolic sequelae associated with ADT for prostate cancer. Curr Opin Endocrinol Diabetes Obes. 2010 Jun; 17(3):240-6

Faris JE, Michaelson MD. Targeted therapies: Sunitinib vs interferon-alpha in metastatic RCC. Nat Rev Clin Oncol. 2010 Jan; 7(1):7-8

Faris JE, LaCasce AS. Primary mediastinal large B-cell lymphoma. Clin Adv Hematol Oncol. 2009 Feb; 7(2):125-33

Faris JE, Moore AF, Daniels GH. Sunitinib-induced thyrotoxicosis due to destructive thyroiditis: a case report. Thyroid. 2007 Nov; 17(11):1147-9.

Hematology/Oncology
55 Fruit Street
Yawkey Center for Outpatient Care, Suite 7E
Boston, MA 02114-2696

Phone: 617-724-4000
Fax: 617-726-0452